Innogenetics and Takeda enter into License Agreement on Takeda's beta-amyloid antibody patents for Alzheimer's Disease
The abnormal accumulation of beta-amyloid protein in the brain is one of the two pathological hallmarks of Alzheimer's disease, and represents a particularly useful diagnostic marker for the disease.
Innogenetics is one of the pioneers in the development and commercialization of novel biochemical markers (biomarkers) for the early and differential diagnosis of Alzheimer's disease and other neurodegenerative disorders.
"This significant license agreement with Takeda strengthens and complements Innogenetics' position in the field of neurodegenerative biomarkers," added Philippe Archinard, Chief Executive Officer of Innogenetics. "The addition of Takeda's beta-amyloid-related patent rights to our proprietary Tau and phospho-Tau patent portfolios underscores Innogenetics' leadership position in the development and marketing of novel diagnostic tools for better and earlier patient diagnosis, and for accelerated drug development."
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous